Dear Colleagues,

Breast cancer is the leading oncological diagnosis in women worldwide, accounting for more than 287,000 cases in 2022. Among multidisciplinary treatment, surgery maintains its leading role in terms of locoregional control, locoregional staging, and risk reduction strategies. However, since the publication of the Milan Trial in 1986, surgical treatment philosophy has shifted from a so-called "maximum tolerable" to a "minimum effective" strategy. Breast-conserving surgery (BCS), as a forerunner, represented the first surgical attempt at de-escalation of surgery, reducing the surgical detrimental effect of patients’ quality of life and patients’ reported outcome (PROM).

In recent years, neoadjuvant chemotherapy, oncoplastic procedure (OPS), and innovative breast reconstruction strategies (e.g., pre-pectoral reconstruction or flap-based reconstruction) overcome the "minimum effective" strategy through the maintenance of breast appearance, providing an opportunity for breast remodeling, enhancing women’s appearance. Finally, innovative technology in breast imaging has provided to breast surgeons an invaluable instrument to design personalized strategies. Under these circumstances, breast surgeons now have a significant number of different strategies to design a real tailored surgical program for each patient.

The present Special Issue will provide an overview of the latest evidence in the field of breast cancer surgery focusing on BCS, oncoplastic surgery, and reconstructive strategy and highlighting their relationship with systemic and other locoregional treatment, and their implications for patients’ quality of life. Therefore, we welcome the submission of case reports, case series, technical notes, review articles, as well as original research papers dealing with oncological outcome or PROM.

Dr. Marco Materazzo
Dr. Maria Rosaria Mastrangeli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• breast carcinoma in situ
• carcinoma, ductal, breast
• breast neoplasms
• mastectomy, segmental
• mammaplasty
• mastectomy
• surgical flaps
• breast implants
• prepectoral breast reconstruction